4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Prelude Therapeutics Incorporated (PRLD) operates in the Biotechnology industry and is headquartered in Wilmington, United States with about 79 employees. Its market capitalization is roughly $391 million. In the fiscal year ended 2025-12-31, PRLD reported $12M in revenue and ($100M) in net income.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Interactive charts & full statements → Open the PRLD valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $12M | $7M | $0M | $0M |
| Operating Income (EBIT) | ($105M) | ($140M) | ($132M) | ($124M) |
| Net Income | ($100M) | ($127M) | ($122M) | ($115M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $5M | $6M | $6M | $0M | $0M |
| Operating Income (EBIT) | ($14M) | ($17M) | ($20M) | ($32M) | ($35M) |
| Net Income | ($10M) | ($16M) | ($20M) | ($31M) | ($32M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $141M | $176M | $278M | $220M | — |
| Total Liabilities | $73M | $44M | $41M | $25M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRLD viewer.
About TickerBase · Data methodology & sources